Table 2.

Clinical data from patients with CML treated with ASC (n = 34)

Patient no.Age at ASC initiation, yYear of CML diagnosisDisease phase at diagnosisDisease phase at ASC initiationPrevious treatmentsNo. of previous linesMutation before ASCOutcome∗ 
1 77 2017 CP CP IM, DASA, and NILO 3 0 Alive, with CCyR 
2 55 2015 CP CP IM and DASA 2 0 Alive, with MMR 
3 44 2021 CP CP IM and NILO 2 0 Alive, MR4.0 
4 48 1998 CP CP IFN, IM, DASA, NILO, and PONA 5 0 Alive, CHR 
5 47 2019 CP CP IM, DASA, and NILO 2 0 Alive, with MMR 
6 82 2020 CP AP IM, DASA, and NILO 3 0 Alive, with AP 
7 34 2017 CP CP IM and DASA 2 0 Alive, with MMR 
8 68 2010 CP CP IM, DASA, and NILO 3 T315I Alive, with CHR 
9 34 1994 CP CP IM, DASA, NILO, and HSCT†  5 0 Alive, with CHR 
10 63 2019 CP CP IM and NILO 2 0 Alive, with DMR 
11 35 2021 CP CP IM and NILO 2 F359V Alive, on DASA 
12 16 2014 CP CP IM, DASA, and PONA 3 E255V/F317L Alive, with DMR 
13 56 2018 CP CP IM, DASA, NILO, and PONA 4 0 Alive, with MMR 
14 40 2017 CP BC IM, DASA, and NILO 3 0 Dead, after HSCT 
15 51 2018 CP BC IM, DASA, NILO, PONA, and HSCT 5 T315I Dead, with BC 
16 55 2021 CP CP IM and DASA 2 T315I Alive, with MMR 
17 67 2022 CP CP IM and DASA 2 Exon 7 deletion Dead, with BC 
18 73 2021 CP CP IM, DASA, and NILO 3 Exon 7 deletion Alive, with CHR 
19 64 2021 CP CP IM and NILO 2 Exon 7 deletion Alive, with CHR 
20 49 2014 CP CP IM, DASA, and NILO 3 0 Alive, with MMR 
21 42 2000 CP CP IM and DASA 2 0 Alive, with CHR 
22 67 1998 AP CP IM, DASA, and NILO 3 E255K Alive, with CHR 
23 74 2012 CP CP IM, DASA, and NILO 3 0 Alive, with DMR 
24 53 2020 CP CP IM, DASA, and PONA 3 T315I Alive, with CHR 
25 77 2007 CP CP IM, DASA, and NILO 3 0 Alive, with MMR 
26 72 2006 CP CP IM, DASA, and NILO 3 0 Alive, with MMR 
27 26 2016 CP AP IM, DASA, and NILO 3 Not done Alive, on PONA 
28 64 2017 CP CP IM and DASA 2 T315I Dead, with BC 
29 83 2004 CP CP IM, DASA, and NILO 3 0 Alive, with CHR 
30 38 2017 CP CP IM, DASA, and NILO 3 0 Dead, with sepsis 
31 47 2018 CP CP IM, DASA, and NILO 3 0 Alive, with MMR 
32 39 2012 CP CP IM, DASA, and NILO 3 0 Alive, after HSCT, on DASA 
33 78 2008 AP AP IM, DASA, and NILO 6 T315I Dead, with BC, on PONA 
34 72 2019 AP AP IM, DASA, and NILO 3 T315I Alive, with MR2 
Patient no.Age at ASC initiation, yYear of CML diagnosisDisease phase at diagnosisDisease phase at ASC initiationPrevious treatmentsNo. of previous linesMutation before ASCOutcome∗ 
1 77 2017 CP CP IM, DASA, and NILO 3 0 Alive, with CCyR 
2 55 2015 CP CP IM and DASA 2 0 Alive, with MMR 
3 44 2021 CP CP IM and NILO 2 0 Alive, MR4.0 
4 48 1998 CP CP IFN, IM, DASA, NILO, and PONA 5 0 Alive, CHR 
5 47 2019 CP CP IM, DASA, and NILO 2 0 Alive, with MMR 
6 82 2020 CP AP IM, DASA, and NILO 3 0 Alive, with AP 
7 34 2017 CP CP IM and DASA 2 0 Alive, with MMR 
8 68 2010 CP CP IM, DASA, and NILO 3 T315I Alive, with CHR 
9 34 1994 CP CP IM, DASA, NILO, and HSCT†  5 0 Alive, with CHR 
10 63 2019 CP CP IM and NILO 2 0 Alive, with DMR 
11 35 2021 CP CP IM and NILO 2 F359V Alive, on DASA 
12 16 2014 CP CP IM, DASA, and PONA 3 E255V/F317L Alive, with DMR 
13 56 2018 CP CP IM, DASA, NILO, and PONA 4 0 Alive, with MMR 
14 40 2017 CP BC IM, DASA, and NILO 3 0 Dead, after HSCT 
15 51 2018 CP BC IM, DASA, NILO, PONA, and HSCT 5 T315I Dead, with BC 
16 55 2021 CP CP IM and DASA 2 T315I Alive, with MMR 
17 67 2022 CP CP IM and DASA 2 Exon 7 deletion Dead, with BC 
18 73 2021 CP CP IM, DASA, and NILO 3 Exon 7 deletion Alive, with CHR 
19 64 2021 CP CP IM and NILO 2 Exon 7 deletion Alive, with CHR 
20 49 2014 CP CP IM, DASA, and NILO 3 0 Alive, with MMR 
21 42 2000 CP CP IM and DASA 2 0 Alive, with CHR 
22 67 1998 AP CP IM, DASA, and NILO 3 E255K Alive, with CHR 
23 74 2012 CP CP IM, DASA, and NILO 3 0 Alive, with DMR 
24 53 2020 CP CP IM, DASA, and PONA 3 T315I Alive, with CHR 
25 77 2007 CP CP IM, DASA, and NILO 3 0 Alive, with MMR 
26 72 2006 CP CP IM, DASA, and NILO 3 0 Alive, with MMR 
27 26 2016 CP AP IM, DASA, and NILO 3 Not done Alive, on PONA 
28 64 2017 CP CP IM and DASA 2 T315I Dead, with BC 
29 83 2004 CP CP IM, DASA, and NILO 3 0 Alive, with CHR 
30 38 2017 CP CP IM, DASA, and NILO 3 0 Dead, with sepsis 
31 47 2018 CP CP IM, DASA, and NILO 3 0 Alive, with MMR 
32 39 2012 CP CP IM, DASA, and NILO 3 0 Alive, after HSCT, on DASA 
33 78 2008 AP AP IM, DASA, and NILO 6 T315I Dead, with BC, on PONA 
34 72 2019 AP AP IM, DASA, and NILO 3 T315I Alive, with MR2 

ASC, asciminib; CCyR, complete cytogenetic response; DASA, dasatinib; DMR, deep molecular response; IFN, interferon; IM, imatinibe; NILO, nilotinib; PONA, ponatinib.

∗

If a patient discontinued ASC, the new drug is cited.

†

The patient underwent 2 transplants.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal